Shenfu Injection attenuates rat myocardial hypertrophy by up-regulating miR-19a-3p expression

Shenfu Injection (SFI) is a classical Chinese medicine used to treat heart failure. Our previous study demonstrated that miRNAs underwent changes in rats with myocardial hypertrophy induced by abdominal aortic constriction. Interestingly, there was a significant change in miR-19a-3p, whose target ge...

Full description

Saved in:
Bibliographic Details
Published in:Scientific reports 2018-03, Vol.8 (1), p.4660-11, Article 4660
Main Authors: Mao, Zhu-Jun, Zhang, Quan-Long, Shang, Jia, Gao, Ting, Yuan, Wen-Jun, Qin, Lu-Ping
Format: Article
Language:English
Subjects:
Aorta
Cardiomyocytes
Chromosome 3
Heart diseases
Hypertrophy
Injection
Major histocompatibility complex
mRNA
Myocardium
Myocyte enhancer factor 2
Overexpression
Proteins
Signal transduction
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Shenfu Injection (SFI) is a classical Chinese medicine used to treat heart failure. Our previous study demonstrated that miRNAs underwent changes in rats with myocardial hypertrophy induced by abdominal aortic constriction. Interestingly, there was a significant change in miR-19a-3p, whose target gene is known to be associated with MEF2 signaling. However, whether and how SFI regulates miR-19a-3p in the treatment of myocardial hypertrophy has not been investigated. The purpose of the present study was to investigate the regulatory effect of SFI on miR-19a-3p in MEF2 signaling in the rat hypertrophic myocardium. We found that the miR-19a-3p expression level was significantly decreased in the hypertrophic myocardium, and MEF2A was the target gene of miR-19a-3p. The protein expressions of MEF2A, β-MHC, BNP and TRPC1 were significantly increased in hypertrophic cardiomyocytes. MiR-19a-3p was up-regulated after SFI treatment, and the protein expressions of these genes were significantly decreased. In addition, miR-19a-3p over-expression in hypertrophic cardiomyocytes could decrease MEF2A mRNA and protein expressions, and anti-miR-19a-3p showed the opposite result. Our study provided substantial evidence that miR-19a-3p played a functional role in MEF2 signaling in myocardial hypertrophy. SFI attenuated cardiomyocyte hypertrophy probably through up-regulating or maintaining the miR-19a-3p levels and regulating the MEF2 signaling pathway.
ISSN:2045-2322
2045-2322
DOI:10.1038/s41598-018-23137-4